{"nctId":"NCT01425632","briefTitle":"A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis","startDateStruct":{"date":"2011-08"},"conditions":["Perennial Allergic Rhinitis"],"count":490,"armGroups":[{"label":"TAU-284 Low","type":"EXPERIMENTAL","interventionNames":["Drug: TAU-284"]},{"label":"TAU-284 High","type":"EXPERIMENTAL","interventionNames":["Drug: TAU-284"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"TAU-284","otherNames":[]},{"name":"TAU-284","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients aged between 7 and 15 years\n* Patients with a weight of at least 20 kg\n* Patients who have received a diagnosis of perennial allergic rhinitis according to the diagnostic criteria\n* Patients with a mean rhinorrhea score of at least 2 and a mean total score for the three major nasal symptoms \\[sneezing, rhinorrhea, and nasal congestion\\] of at least 4 on the basis of symptoms recorded in the nasal allergy diary during the observation period\n\nExclusion Criteria:\n\n* Patients with vasomotor rhinitis or eosinophilic rhinitis\n* Patients who have concurrent nasal disease that may affect the efficacy of TAU-284\n* Patients with a history of any of the nasal surgical procedures\n* Patients who have a positive result for pollen antigens which are dispersed during the study period\n* Patients who have a positive result for dog dander or cat dander antigen\n* Patients with current or previous history of drug allergy\n* Patients who concurrently have renal function abnormalities that may cause safety problems","healthyVolunteers":false,"sex":"ALL","minimumAge":"7 Years","maximumAge":"15 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion] (at Final Evaluation)","description":"Total score for the three major nasal symptoms (sneezing, rhinorrhea, and nasal congestion) were rated on 4-point scale ranging from 0 (no symptoms) to 3 (severe) .","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.84","spread":"0.12"},{"groupId":"OG001","value":"-0.92","spread":"0.12"},{"groupId":"OG002","value":"-0.70","spread":"0.12"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion]","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Individual Nasal Symptom Scores (Sneezing, Rhinorrhea, Nasal Congestion, and Impairment in Daily Activities)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Individual Scores for Local Nasal Findings (Rhinoscopic Findings)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Severity Score","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Adverse Events and Adverse Drug Reactions","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Plasma Concentrations of Unchanged TAU-284 (Bepotastine Besilate) (at a Total of 3 Time Points, i.e., Before and 2 (Â±1) Hours After Study-drug Administration at Week 1 and Before Study-drug Administration at Week 2)","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":161},"commonTop":["Nasopharyngitis","Pharyngitis","Epistaxis"]}}}